

- --- Intravenous EPOGEN
- → Subcutaneous EPOGEN
- Subcutaneous MR-NGE
- → Intravenous MR-NGE

FIG. 3A






FIG. 3B



SUBSTITUTE SHEET (RULE 26)

4/15







FIG. 5



**SUBSTITUTE SHEET (RULE 26)** 

**BEST AVAILABLE COPY** 

FIG. 6A





FIG. 6B



SUBSTITUTE SHEET (RULE 26)

FIG. 6C







FIG. 6D



SUBSTITUTE SHEET (RULE 26)

FIG. 7A





SUBSTITUTE SHEET (RULE 26)

FIG. 8





FIG. 9A




 $log(U/mg)=5.48(\pm 0.10)-0.55(\pm 0.04)$  Degree of PEGylation

intercept: Prob>[t]<0.0001 slope: Prob>[t]<0.0001

R<sup>2</sup>:0.92

FIG. 9B




log(U/mg)=5.41-0.63 Degree of PEGylation

intercept: Prob>[t]<0.0001 slope: Prob>[t]<0.0001


 $R^2:0.75$ 

FIG. 10




- ▲ 100 ug/kg, s.c. dose
  □ 50 ug/kg, s.c. dose
   20 ug/kg, s.c. dose

FIG. 11




- 20 ug/kg, s.c. dose
- □ 50 ug/kg, s.c. dose
- ▲ 100 ug/kg, s.c. dose



- $\diamondsuit$  Cmpd AM [PEG(20kDa)<sub>3.3</sub>]
- ▲ Cmpd F [PEG(20kDa)<sub>2.5</sub>]
- ☐ Cmpd G [PEG(20kDa)<sub>2.1</sub>]
- ▼ Cmpd Z [PEG(20kDa)<sub>1.0</sub>]
- O Cmpd Epo

FIG. 13



PBS/BSA

Epo AM

